Skip to main content
H.R. 4369 117th Congress House

National Centers of Excellence in Advanced and Continuous Pharmaceutical Manufacturing Act of 2021

Official title: To amend the 21st Century Cures Act to provide for designation of institutions of higher education that provide research, data, and leadership on advanced and … Show full official titleShow less

Official title: To amend the 21st Century Cures Act to provide for designation of institutions of higher education that provide research, data, and leadership on advanced and continuous pharmaceutical manufacturing as National Centers of Excellence in Advanced and Continuous Pharmaceutical Manufacturing, and for other purposes.

Introduced: July 6, 2021 Introduced by: Frank Pallone, Jr. Democratic · New Jersey See on congress.gov
Health Advanced technology and technological innovationsCongressional oversightDepartment of Health and Human ServicesDrug safety, medical device, and laboratory regulation
More subjectsShow fewer subjects
Food and Drug Administration (FDA)Government information and archivesHealth programs administration and fundingHealth technology, devices, suppliesHigher educationManufacturingPrescription drugsProduct development and innovationResearch administration and fundingResearch and development
Sign in to write a letter

Free account. One morning email at most, only on days something moved. Already have one? Sign in.

This bill died when the 117th Congress ended
It never became law before the 117th Congress (2021–2022) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 18 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Oct 20, 2021
Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Oct 19, 2021
On motion to suspend the rules and pass the bill, as amended Agreed to by the Yeas and Nays: (2/3 required): 368 - 56 (Roll no. 318). (text: CR H5645-5647)
Oct 19, 2021
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 117-151.
Oct 19, 2021
The title of the measure was amended. Agreed to without objection.
Oct 19, 2021
Motion to reconsider laid on the table Agreed to without objection.
Oct 19, 2021
Considered as unfinished business. (consideration: CR H5662-5663)
Oct 19, 2021
At the conclusion of debate, the Yeas and Nays were demanded and ordered. Pursuant to the provisions of clause 8, rule XX, the Chair announced that further proceedings on the motion would be postponed.
Oct 19, 2021
DEBATE - The House proceeded with forty minutes of debate on H.R. 4369.
Oct 19, 2021
Considered under suspension of the rules. (consideration: CR H5645-5647)
Oct 19, 2021
Mr. Pallone moved to suspend the rules and pass the bill, as amended.
Oct 19, 2021
Placed on the Union Calendar, Calendar No. 111.
Jul 21, 2021
Ordered to be Reported (Amended) by Voice Vote.
Jul 21, 2021
Committee Consideration and Mark-up Session Held.
Jul 15, 2021
Forwarded by Subcommittee to Full Committee (Amended) by Voice Vote .
Jul 15, 2021
Subcommittee Consideration and Mark-up Session Held.
Jul 7, 2021
Referred to the Subcommittee on Health.
Jul 6, 2021
Introduced in House
Jul 6, 2021
Referred to the House Committee on Energy and Commerce.
 Votes taken on this bill 1
DateChamberWhat was voted onResultYes–No
Oct 19, 2021 House · vote #318 On Motion to Suspend the Rules and Pass, as Amended Passed 368–56 See who voted →
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Latest action October 20, 2021

Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

 Plain-English summary Congressional Research Service

National Centers of Excellence in Advanced and Continuous Pharmaceutical Manufacturing Act of 2021

This bill directs the Food and Drug Administration (FDA) to designate qualified institutions of higher education (or consortia of such institutions) as National Centers of Excellence in Advanced and Continuous Pharmaceutical Manufacturing and to provide grants to the centers. Each designated center must conduct research on advanced and continuous pharmaceutical manufacturing technologies and must share information from such research with the FDA. (Currently, most drug production involves batch manufacturing, which typically takes longer than continuous manufacturing processes.)

 Related & companion bills 1
  • S 2589 Securing America’s Medicine Cabinet Act of 2021
 Bill text 4 versions

Source documents hosted by congress.gov.

 Committees of jurisdiction 3
 Lobbying activity 2

Registered lobbyists who named this bill in their disclosure filings. Source: federal Lobbying Disclosure Act filings.

Bodies those filers lobbied

A filing lists the bills it worked on and the parts of government it contacted in separate sections, so these are the bodies those filers named anywhere in the filing, not a per-bill breakdown.

 Cosponsors 1
All 1 Republican 1
R
Guthrie, Brett
Kentucky · Jul 6, 2021
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 4369: National Centers of Excellence in Advanced and Continuous Pharmaceutical Manufacturing Act of 2021. 117th Congress. Open America. https://openamerica.io/bill/117-HR-4369/
MLA
"H.R. 4369: National Centers of Excellence in Advanced and Continuous Pharmaceutical Manufacturing Act of 2021." 117th Congress, 2026, Open America, https://openamerica.io/bill/117-HR-4369/.
Bluebook (legal)
H.R. 4369, 117th Cong. (2026), https://openamerica.io/bill/117-HR-4369/.
Markdown link
[H.R. 4369: National Centers of Excellence in Advanced and Continuous Pharmaceutical Manufacturing Act of 2021](https://openamerica.io/bill/117-HR-4369/)
Report a problem